Acumen pharmaceuticals presents positive topline results from first-in-human phase 1 study of acu193 for early alzheimer's disease at the alzheimer's association international conference (aaic) 2023

Charlottesville, va. and carmel, ind., july 16, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today presented positive topline results from the phase 1 intercept-ad trial of acu193, the first clinical-stage aΒo targeting antibody therapy in early ad, at the alzheimer's association international conference (aaic®) 2023, taking place in amsterdam and online from july 16-20, 2023.
ABOS Ratings Summary
ABOS Quant Ranking